OPKO Health, Inc.
Informe acción TASE:OPK
Capitalización de mercado: ₪4.0b
OPKO Health Dividendos y recompras
Dividendo controles de criterios 0/6 OPKO Health no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
6.9%
Rendimiento de la recompra
Rendimiento total para el accionista 6.9% Rendimiento futuro de los dividendos n/a Crecimiento de los dividendos n/a Próxima fecha de pago de dividendos n/a Fecha ex dividendo n/a Dividendo por acción n/a Ratio de pago n/a
Últimas actualizaciones de dividendos y recompras OPKO Health, Inc. (NasdaqGS:OPK) announces an Equity Buyback for $100 million worth of its shares. Jul 20
Mostrar todas las actualizaciones
New minor risk - Profitability Nov 12
Chairman & CEO recently bought ₪1.6m worth of stock Nov 10
OPKO Health, Inc. Provides Financial Guidance for the Fourth Quarter 2024 Nov 09
Third quarter 2024 earnings released: EPS: US$0.036 (vs US$0.11 loss in 3Q 2023) Nov 09
OPKO Health, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 30
Second quarter 2024 earnings released: US$0.015 loss per share (vs US$0.026 loss in 2Q 2023) Aug 08
OPKO Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 02 OPKO Health, Inc. (NasdaqGS:OPK) announces an Equity Buyback for $100 million worth of its shares. Jul 20
OPKO Health, Inc. announced that it has received $250 million in funding from Healthcare Royalty Management, LLC Jul 18
Chairman & CEO recently bought ₪466k worth of stock Jun 01
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome Mar 20 OPKO Health, Inc. announced delayed annual 10-K filing Mar 03
New major risk - Financial position Feb 29
Full year 2023 earnings released: US$0.25 loss per share (vs US$0.46 loss in FY 2022) Feb 28
Chairman & CEO recently bought ₪3.6m worth of stock Feb 25
OPKO Health, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 23 OPKO Health, Inc., Annual General Meeting, Mar 28, 2024
Chairman & CEO recently bought ₪5.3m worth of stock Feb 10
Independent Director recently bought ₪109k worth of stock Jan 30
Lead Independent Director recently bought ₪86k worth of stock Jan 07
New minor risk - Profitability Jan 06
Chairman & CEO recently bought ₪4.9m worth of stock Nov 14
Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2022) Nov 07
OPKO Health, Inc. Presents Late-Breaking Clinical Data on RAYALDEE Extended-Release Calcifediol Nov 03
OPKO Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Nov 01
Chairman & CEO recently bought ₪4.4m worth of stock Aug 09
Second quarter 2023 earnings released: US$0.026 loss per share (vs US$0.14 loss in 2Q 2022) Aug 05
OPKO Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 26
New minor risk - Profitability Jul 02
Chief Innovation Officer & Director recently bought ₪2.0m worth of stock May 09
First quarter 2023 earnings released: US$0.024 loss per share (vs US$0.084 loss in 1Q 2022) May 06
Chairman & CEO recently bought ₪958k worth of stock Mar 26
Chairman & CEO recently bought ₪4.2m worth of stock Mar 16
Full year 2022 earnings released: US$0.46 loss per share (vs US$0.047 loss in FY 2021) Feb 26
OPKO Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 17
Chairman & CEO recently bought ₪1.6m worth of stock Nov 25
Chairman & CEO recently bought ₪1.1m worth of stock Nov 16
Chairman & CEO recently bought ₪1.1m worth of stock Nov 11
Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.044 profit in 3Q 2021) Nov 10
OPKO Health, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Chairman & CEO recently bought ₪469k worth of stock Oct 12
Chairman & CEO recently bought ₪1.4m worth of stock Sep 17
Chairman & CEO recently bought ₪722k worth of stock Sep 07
Chairman & CEO recently bought ₪1.7m worth of stock Aug 20
OPKO Health, Inc. Announces Leadership Changes for Bioreference Laboratories Aug 17
Chairman & CEO recently bought ₪2.7m worth of stock Aug 09 OPKO Health, Inc. Provides Revenue Guidance for the Year 2022
Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.025 loss in 2Q 2021) Aug 05
OPKO Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 26
OPKO Health, Inc., Annual General Meeting, Jul 14, 2022 Jun 04
Chairman & CEO recently bought ₪3.9m worth of stock May 12
First quarter 2022 earnings released: US$0.084 loss per share (vs US$0.048 profit in 1Q 2021) May 10 OPKO Health, Inc. (NasdaqGS:OPK) acquired ModeX Therapeutics, Inc. for $300 million. May 10
OPKO Health, Inc. to Report Q1, 2022 Results on May 09, 2022 May 06
Chairman & CEO recently bought ₪349k worth of stock Mar 21
Chairman & CEO recently bought ₪7.5m worth of stock Mar 04
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
OPKO Health, Inc. Provides Revenue Guidance for the Year 2022 Feb 26
Chairman & CEO recently bought ₪988k worth of stock Feb 19
OPKO Health, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
OPKO Health, Inc. Announces That Vifor Fresenius Medical Care Renal Pharma has Initiated the Commercial Launch of Rayaldee® in Germany Feb 04
Chairman & CEO recently bought ₪3.3m worth of stock Jan 30
Investor sentiment deteriorated over the past week Jan 24
Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency Jan 22
Sema4 Holdings Corp. (NasdaqGS:SMFR) entered into an agreement to acquire GeneDx, Inc. from OPKO Health, Inc. (NasdaqGS:OPK) for approximately $620 million. Jan 20
OPKO Health, Inc. Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients Dec 24
Opko Health Receives U.S. FDA Approval for the 4Kscore Test Dec 09
Investor sentiment improved over the past week Nov 04
Third quarter 2021 earnings released: EPS US$0.044 (vs US$0.037 in 3Q 2020) Oct 29
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency Sep 25
Chairman & CEO recently bought ₪1.1m worth of stock Sep 16
Chairman & CEO recently bought ₪1.2m worth of stock Aug 18
Second quarter 2021 earnings released: US$0.025 loss per share (vs US$0.053 profit in 2Q 2020) Jul 31
Chairman & CEO recently bought ₪2.4m worth of stock Jun 17
Chairman & CEO recently bought ₪4.7m worth of stock May 27
Chairman & CEO recently bought ₪321k worth of stock May 07
First quarter 2021 earnings released: EPS US$0.048 (vs US$0.092 loss in 1Q 2020) May 01
Chairman & CEO recently bought ₪3.9m worth of stock Mar 11
Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de OPK han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de OPK han aumentado.
Rentabilidad por dividendo vs. Mercado Rentabilidad por dividendo de OPKO Health vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de OPK con la del mercado? Segmento Rentabilidad por dividendo Empresa (OPK) n/a Suelo de mercado 25% (IL) 2.3% Techo de mercado 25% (IL) 6.3% Media de la industria (Healthcare) 4.9% Analista de previsiones (OPK) (hasta 3 años) n/a
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de OPK en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de OPK en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de OPK para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que OPK no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}